Jaques A Courtade1,2, Agnieszka M Klimek-Abercrombie1,2, Yi-Chun Chen2,3, Nirja Patel4, Phoebe Y T Lu2,5, Cate Speake6, Paul C Orban1,2, Behzad Najafian7, Graydon Meneilly8, Carla J Greenbaum6, Garth L Warnock3, Constadina Panagiotopoulos2,8, C Bruce Verchere1,2,3. 1. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V5Z 4H4, Canada. 2. Research Institute, BC Children's Hospital, Vancouver, British Columbia V5Z 4H4, Canada. 3. Department of Surgery, University of British Columbia, Vancouver, British Columbia V5Z 4H4, Canada. 4. American Laboratory Products Company, Salem, New Hampshire 03079. 5. Department of Genetics, University of British Columbia, Vancouver, British Columbia V5Z 4H4, Canada. 6. Diabetes Clinical Research Program, Benaroya Research Institute, Seattle, Washington 98101. 7. Department of Pathology, University of Washington, Seattle, Washington 98195. 8. Department of Medicine, University of British Columbia, Vancouver, British Columbia V5Z 4H4, Canada.
Abstract
Context: Islet amyloid is a feature of β-cell failure in type 2 diabetes (T2D) and type 1 diabetes (T1D) recipients of islet transplants. Islet amyloid contains islet amyloid polypeptide (IAPP; amylin), a circulating peptide that is produced in β cells by processing of its precursor, proIAPP1-67, via an intermediate form, proIAPP1-48. Elevated proinsulin to C-peptide ratios in the plasma of persons with diabetes suggest defects in β-cell prohormone processing. Objective: Determine whether plasma levels of precursor forms of IAPP are elevated in diabetes. Design, Setting, and Patients: We developed an immunoassay to detect proIAPP1-48 in human plasma, and we determined the ratio of proIAPP1-48 to mature IAPP in subjects with T1D, T2D, recipients of islet transplants, and healthy controls. Results: The proIAPP1-48 immunoassay had a limit of detection of 0.18 ± 0.06 pM and cross-reactivity with intact proIAPP1-67 <15%. Healthy individuals had plasma concentrations of proIAPP1-48 immunoreactivity of 1.5 ± 0.2 pM and a proIAPP1-48 to total IAPP ratio of 0.28 ± 0.03. Plasma concentrations of proIAPP1-48 immunoreactivity were not significantly different in subjects with T2D but were markedly increased in T1D recipients of islet transplants. Children and adults with T1D had reduced mature IAPP levels relative to age-matched controls but an elevated ratio of proIAPP1-48 to total IAPP. Conclusion: The β cells in T1D and islet transplants have impaired processing of the proIAPP1-48 intermediate. The ratio of proIAPP1-48-to-IAPP immunoreactivity may have value as a biomarker of β-cell stress and dysfunction.
Context: Islet amyloid is a feature of β-cell failure in type 2 diabetes (T2D) and type 1 diabetes (T1D) recipients of islet transplants. Islet amyloid contains islet amyloid polypeptide (IAPP; amylin), a circulating peptide that is produced in β cells by processing of its precursor, proIAPP1-67, via an intermediate form, proIAPP1-48. Elevated proinsulin to C-peptide ratios in the plasma of persons with diabetes suggest defects in β-cell prohormone processing. Objective: Determine whether plasma levels of precursor forms of IAPP are elevated in diabetes. Design, Setting, and Patients: We developed an immunoassay to detect proIAPP1-48 in human plasma, and we determined the ratio of proIAPP1-48 to mature IAPP in subjects with T1D, T2D, recipients of islet transplants, and healthy controls. Results: The proIAPP1-48 immunoassay had a limit of detection of 0.18 ± 0.06 pM and cross-reactivity with intact proIAPP1-67 <15%. Healthy individuals had plasma concentrations of proIAPP1-48 immunoreactivity of 1.5 ± 0.2 pM and a proIAPP1-48 to total IAPP ratio of 0.28 ± 0.03. Plasma concentrations of proIAPP1-48 immunoreactivity were not significantly different in subjects with T2D but were markedly increased in T1D recipients of islet transplants. Children and adults with T1D had reduced mature IAPP levels relative to age-matched controls but an elevated ratio of proIAPP1-48 to total IAPP. Conclusion: The β cells in T1D and islet transplants have impaired processing of the proIAPP1-48 intermediate. The ratio of proIAPP1-48-to-IAPP immunoreactivity may have value as a biomarker of β-cell stress and dysfunction.
Authors: Emily K Sims; Carmella Evans-Molina; Sarah A Tersey; Decio L Eizirik; Raghavendra G Mirmira Journal: Diabetologia Date: 2018-08-15 Impact factor: 10.122
Authors: Emily K Sims; Farooq Syed; Julius Nyalwidhe; Henry T Bahnson; Leena Haataja; Cate Speake; Margaret A Morris; Appakalai N Balamurugan; Raghavendra G Mirmira; Jerry Nadler; Teresa L Mastracci; Peter Arvan; Carla J Greenbaum; Carmella Evans-Molina Journal: Transl Res Date: 2019-08-09 Impact factor: 7.012
Authors: Teresa Rodriguez-Calvo; Yi-Chun Chen; C Bruce Verchere; Leena Haataja; Peter Arvan; Pia Leete; Sarah J Richardson; Noel G Morgan; Wei-Jun Qian; Alberto Pugliese; Mark Atkinson; Carmella Evans-Molina; Emily K Sims Journal: Diabetes Date: 2021-05-04 Impact factor: 9.337
Authors: Steven E Kahn; Yi-Chun Chen; Nathalie Esser; Austin J Taylor; Daniël H van Raalte; Sakeneh Zraika; C Bruce Verchere Journal: Endocr Rev Date: 2021-09-28 Impact factor: 25.261